327 results on '"Kwak, Larry W."'
Search Results
2. Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies
3. Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4. Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies
5. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial
6. CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia
7. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
8. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
9. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma
10. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
11. Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions
12. Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
13. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma
14. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
15. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma
16. The changing investment in translational science by academic medical centers: HOPE in the Valley of Death
17. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
18. Toll-like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2
19. Targeting myeloid-derived suppressor cells for cancer immunotherapy
20. Vaccination with Syngeneic, Lymphoma-Derived Immunoglobulin Idiotype Combined with Granulocyte/Macrophage Colony-Stimulating Factor Primes Mice for a Protective T-Cell Response
21. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial
22. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
23. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma
24. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
25. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation
26. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
27. Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
28. Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
29. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial
30. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP
31. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
32. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas
33. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
34. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities
35. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma
36. Rush Hour Traffic: Directing T Cells to Tumor
37. Translational development of vaccination strategies in follicular NHL
38. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma
39. Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma
40. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice
41. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
42. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
43. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
44. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
45. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells
46. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity
47. Myeloma cell line–derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
48. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
49. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach
50. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.